

**FORM 51-102F3
MATERIAL CHANGE REPORT
UNDER NATIONAL INSTRUMENT 51-102**

Item 1 Name and Address of Company

Abattis Bioceuticals Corp. (the "Issuer")
104 - 9295 198th Street,
Langley, B.C., V1M 3J9

Item 2 Date of Material Change

August 10, 2016

Item 3 News Release

A news release was disseminated on August 10, 2016 through the facilities of NewsFile and subsequently filed on SEDAR.

Item 4 Summary of Material Change

On August 10, 2016, Abattis Bioceuticals Corp. (the "**Company**" or "**Abattis**") (OTCQX: ATTFB) (CSE: ATT) announced that it has entered an exclusive distribution agreement with the Jiangsu Regent Granary Trading Co., Ltd. for distribution of the Company's products in mainland China. The Company also announced the resignation of Michael Yung, the Company's Chief Executive Officer. Mr. Rene David will be acting as the interim-CEO until the board appoints a new Chief Executive Officer.

Item 5 Full Description of Material Change

Abattis announced that it has entered into an exclusive distribution agreement with the Jiangsu Regent Granary Trading Co., Ltd. ("Jaingsu"). Jaingsu is one of a select few that is exporting Canadian beef to China. They also export granola, dried fruit and will also include Abattis' line of PhytNos Superfruit tonics and VitaGum in mainland China. Jaingsu will utilize its network and sales experience to cultivate a market for Abattis' offerings. Jaingsu has certain sales revenue targets under the agreement; failure to achieve such targets will allow Abattis to terminate such agreement.

The key benefit is mainly access to our own distribution personnel in China. The market is vast and demand is very high for North American health products and technology that Abattis can offer.

The Company also announced that Michael Yung the Chief Executive Officer of Abattis has resigned. Mr. Yung will be replaced by Mr. Rene David on an interim basis while the board of directors appoints a new CEO.

These are exciting times for Abattis and the state of the Medical Cannabis industry and we wish to thank Mr. Yung for assisting with our most recent sales and marketing effort into Asia where we have made great progress from our recent trips to Shanghai and Korea. We wish Mr. Yung the best of luck with his new project.

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

N/A

Item 7 Omitted Information

N/A

Item 8 Executive Officer

Rene David

CFO

Abattis Bioceuticals Corp.

Tel: 604.336.0881

Item 9 Date of Report

August 16, 2016

Cautionary Note Regarding Forward Looking Statements

This material change report contains certain forward-looking statements about the Company's future plans and intentions, including statements relating to the Company's intention to implement changes across its business to achieve growth. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict", "scheduled" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect Management's current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.